Exploring the path to selective TRK inhibition
Research suggests that some patients develop cancer because of a gene abnormality involving a protein known as tropmyosin recepter kinase (TRK). Larotrectinib (LOXO-101) is an investigational medicine designed to selectively target TRK fusions. Clinical efficacy and safety is currently being investigated for pediatric and adult patients whose tumors harbor a TRK fusion.
Get the facts on TRK testing >
Read more about larotrectinib >